Successful treatments for allergic bronchopulmonary aspergillosis in non-cystic fibrosis children: a report of two cases and a literature review

Allergic bronchopulmonary aspergillosis (ABPA) is a disease induced by an exaggerated immune response to Aspergillus fumigatus, often occurring in susceptible adult patients with asthma and cystic fibrosis (CF). Proper treatments can alleviate symptoms, reduce pulmonary infiltrates and prevent progression of lung destruction. However, treatment experiences in ABPA children without CF are limited. Here we present two cases of successful treatments of ABPA in non-CF pediatric patients in China. We also present a literature review of ABPA treatments in 15 children without CF from 1971 to 2015. Based on these two cases, and our literature review, we recommend long-term low-dose oral corticosteroid therapy combined with antifungal agents along with close monitoring for these children, and suggest that anti-IgE therapy is not necessary.